Collegium Pharmaceutical (COLL) Receivables - Net (2016 - 2026)

Collegium Pharmaceutical's Receivables - Net history runs 11 years deep, the most recent figure standing at $228.8 million for Q1 2026.

• On a quarterly basis, Receivables - Net changed 0.02% year-over-year to $228.8 million in Q1 2026; TTM through Mar 2026 was $228.8 million, a 0.02% change from a year earlier, with the FY2025 full-year figure at $211.3 million, down 7.53% from the prior year.
• Receivables - Net rose to $228.8 million in Q1 2026 per COLL's latest filing, from $211.3 million in the prior quarter.
• Across five years, Receivables - Net topped out at $233.9 million in Q3 2025 and bottomed at $166.3 million in Q1 2022.
• The 5-year median for Receivables - Net is $195.4 million (2022), against an average of $198.9 million.
• Across the five-year window, Receivables - Net jumped 119.21% in 2022 and slipped 15.2% in 2023, its largest moves.
• Year by year, Receivables - Net stood at $183.1 million in 2022, then declined by 1.96% to $179.5 million in 2023, then gained by 27.3% to $228.5 million in 2024, then retreated by 7.53% to $211.3 million in 2025, then climbed by 8.25% to $228.8 million in 2026.
• Per Business Quant, the three latest COLL Receivables - Net figures stand at $228.8 million (Q1 2026), $211.3 million (Q4 2025), and $233.9 million (Q3 2025).